QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)

Neoleukin Therapeutics - NLTX Stock Forecast, Price & News

$0.60
+0.02 (+3.48%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.58
$0.60
50-Day Range
$0.41
$0.61
52-Week Range
$0.38
$3.84
Volume
42,115 shs
Average Volume
133,816 shs
Market Capitalization
$25.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Neoleukin Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
916.4% Upside
$6.00 Price Target
Short Interest
Healthy
0.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.04) to ($0.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.71 out of 5 stars

Medical Sector

75th out of 1,055 stocks

Pharmaceutical Preparations Industry

25th out of 518 stocks


NLTX stock logo

About Neoleukin Therapeutics (NASDAQ:NLTX) Stock

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

Receive NLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NLTX Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Mizuho Securities downgrades Neoleukin Therapeutics (NLTX) to a Hold
5 Analysts Have This to Say About Neoleukin Therapeutics
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Recap: Neoleukin Therapeutics Q4 Earnings
See More Headlines
Receive NLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NLTX Company Calendar

Last Earnings
11/14/2022
Today
1/31/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NLTX
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+908.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
8 Analysts

Profitability

Net Income
$-60,690,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.37 per share

Miscellaneous

Free Float
36,721,000
Market Cap
$25.34 million
Optionable
Optionable
Beta
1.11

Key Executives

  • Jonathan G. DrachmanJonathan G. Drachman
    President, Chief Executive Officer, CFO & Director
  • Priti Patel
    Chief Medical Officer
  • Bill Arthur
    Head-Research & Vice President
  • Carl WalkeyCarl Walkey
    Senior Vice President-Corporate Development
  • Sean Smith
    Chief Accounting Officer













NLTX Stock - Frequently Asked Questions

Should I buy or sell Neoleukin Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neoleukin Therapeutics in the last year. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NLTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NLTX, but not buy additional shares or sell existing shares.
View NLTX analyst ratings
or view top-rated stocks.

What is Neoleukin Therapeutics' stock price forecast for 2023?

8 analysts have issued 1-year target prices for Neoleukin Therapeutics' stock. Their NLTX share price forecasts range from $2.00 to $10.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 900.0% from the stock's current price.
View analysts price targets for NLTX
or view top-rated stocks among Wall Street analysts.

How have NLTX shares performed in 2023?

Neoleukin Therapeutics' stock was trading at $0.5090 on January 1st, 2023. Since then, NLTX shares have increased by 17.9% and is now trading at $0.60.
View the best growth stocks for 2023 here
.

When is Neoleukin Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our NLTX earnings forecast
.

How were Neoleukin Therapeutics' earnings last quarter?

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.08.

What other stocks do shareholders of Neoleukin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Pfizer (PFE), Raytheon Technologies (RTX), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), CVS Health (CVS), Fulcrum Therapeutics (FULC) and Home Depot (HD).

What is Neoleukin Therapeutics' stock symbol?

Neoleukin Therapeutics trades on the NASDAQ under the ticker symbol "NLTX."

Who are Neoleukin Therapeutics' major shareholders?

Neoleukin Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, Carl Walkey, Jonathan G Drachman, Priti Patel, Redmile Group, Llc, Robert Ho and Sean Michael Smith.
View institutional ownership trends
.

How do I buy shares of Neoleukin Therapeutics?

Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neoleukin Therapeutics' stock price today?

One share of NLTX stock can currently be purchased for approximately $0.60.

How much money does Neoleukin Therapeutics make?

Neoleukin Therapeutics (NASDAQ:NLTX) has a market capitalization of $25.55 million. The company earns $-60,690,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis.

How can I contact Neoleukin Therapeutics?

Neoleukin Therapeutics' mailing address is 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102. The official website for the company is www.neoleukin.com. The company can be reached via phone at (866) 245-0312, via email at investors@neoleukin.com, or via fax at 778-331-4486.

This page (NASDAQ:NLTX) was last updated on 1/31/2023 by MarketBeat.com Staff